

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS. LAST 12 Month	REGS. LAST 6 Month	REGS. LAST 3 Month	REGS. LAST 30 DAYS	REGS. LAST 7 DAYS	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
SWOG	S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424	1 Y	1 OBI-3424 8mg	67	5	0	0	0	0	0	02/08/2021	74	28
			2 OBI-3424 10mg		5	0	0	0	0	0			
			3 OBI-3424 12mg		9	5	1	1	0	0			
					19	5	1	1	0	0			
	S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O	1 Y	1 Delayed V-O	247	49	14	8	3	0	0	03/02/2021	258	99
			2 Early V-O		93	28	15	9	3	2			
					142	42	23	12	3	2			
	MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental	1 Y	1 Daunorubicin + Cytarabine	335	3	3	3	1	0	0	09/25/2024	254	88
			2 Venetoclax + Daunorubicin + Cytarabine		3	3	3	2	0	0			
			3 Venetoclax + Azacitidine		3	3	2	2	1	0			
			4 (Daunorubicin + Cytarabine) Liposome		3	3	2	1	0	0			
			5 (Daunorubicin + Cytarabine) Liposome + Venetoclax		2	2	1	1	0	0			
					14	14	11	7	1	0			
	MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials	1 Y	1 Screening		436	436	347	172	36	4	06/18/2024	317	123
					436	436	347	172	36	4			
		2 Y	2 Re-screening		39	39	38	25	1	0	06/18/2024		
					39	39	38	25	1	0			
		3 Y	3 Re-screening		4	4	4	3	1	0	06/18/2024		
					4	4	4	3	1	0			
		4 Y	4 Re-screening		1	1	1	1	0	0	06/18/2024		
					1	1	1	1	0	0			
Yes	EA9213-T-ALL, dara-hyal for chemo refractory MRD	0 E	Total Registrations		6	1	1	0	0	0	02/24/2023	87	18
					6	1	1	0	0	0			
		1 E	Total Registrations		3	0	0	0	0	0	02/24/2023		
					3	0	0	0	0	0			

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
					LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
No	A041501-B-Cell ALL, Frontline Tx +/- Inotuzumab Ozo	0 E Total Registrations		71	0	0	0	0	0	11/09/2018	243	85
				71	0	0	0	0	0			
		1 E Total Registrations		57	0	0	0	0	0	11/09/2018		
				57	0	0	0	0	0			
		2 E Total Registrations		44	0	0	0	0	0	11/09/2018		
				44	0	0	0	0	0			
	A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat	0 E Total Registrations		11	0	0	0	0	0	08/13/2020	137	49
				11	0	0	0	0	0			
		1 E Total Registrations		5	0	0	0	0	0	08/13/2020		
				5	0	0	0	0	0			
	EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab	0 E Total Registrations		52	13	7	2	1	0	02/19/2021	157	55
				52	13	7	2	1	0			
		1 E Total Registrations		43	10	6	2	1	0	02/19/2021		
				43	10	6	2	1	0			
		2 E Total Registrations		37	9	4	2	1	0	02/19/2021		
				37	9	4	2	1	0			
	MM10AEA02-MyeloMATCH: AML, New Dx, Ven+HMA	1 E Total Registrations		3	3	3	0	0	0	12/02/2024	260	81
				3	3	3	0	0	0			
	MM1YACTG01-AML, New/Young/Intermediate, Ven+Chemo	1 E Total Registrations		2	2	0	0	0	0	10/14/2024	215	72
				2	2	0	0	0	0			

LEUK Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>	<u># of ACT. INSTs</u>	<u># of CURR IRBs</u>
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab	3 Randomization	14-Oct-20	157	55
MM10A-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena	1 Registration	01-Apr-25	112	26